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Hepatosplenic T-cell lymphoma (HSTCL), a rare type of γδ T-cell lymphoma, is characterized by hepa-
tosplenomegaly and cytopenias. It is associated with immunodeﬁciency and its age of onset is reportedly
between the 20s and 30s. We herein report 4 Japanese HSTCL cases. Three of them, including an elderly
case that was 74 years of age, were not at adolescence. No cases had a history of immunodeﬁciency. All
other disease phenotypes were similar to the typical HSTCL cases. These ﬁndings suggest that there are a
certain proportion of HSTCL patients who presented after middle age.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of
peripheral T-cell lymphoma, which is derived from cytotoxic T-cells
typically expressing γδ T-cell receptor (TCR). It usually occurs in
young men and is characterized by B symptoms such as a fever,
weight loss and night sweats, hepatosplenomegaly, thrombocyto-
penia, and anemia. The patient's prognosis is typically poor [1].
Approximately 20% of all HSTCL cases are associated with im-
munodeﬁciency which include chronic immunosuppressive
therapies after solid-organ transplantation and collagen diseases
such as SLE, HIV, malaria infection, AML, Hodgkin's lymphoma,
and inﬂammatory bowel diseases [2], suggesting that the im-
munodeﬁcient status may contribute to the development of
HSTCL.
Histologically, the lymphoma cells have medium-sized nuclei
and a rim of pale cytoplasm, and homogeneous medium-sized
CD3-positive lymphoma cells inﬁltrate the cords and sinuses in the
red pulp of the spleen, sinusoids of the liver and the bone marrow
[1]. Immunohistochemistry analyses generally show CD3(þ), CD4
(), CD5(), CD8(/þ), CD56(þ/), TCRδ1(þ), TIA-1(þ), and
granzyme B().Ltd. This is an open access article u
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atsushita),HSTCL accounts for only 3% of all T-cell lymphomas in the
United States and 2.3% in Europe. Notably, it occurs less frequently
in Eastern and South-eastern Asian countries (0.2%) [3]. Because
HSTCL is especially rare in Asia, its actual characteristics in Asia
have not been well-documented [4]. We experienced 4 cases of
HSTCL out of 292 cases (1.3%) of T cell lymphoma according to the
clinical and pathological records between 1998 and 2014 in our
institution. Surprisingly, 3 out of the 4 cases were middle-aged to
elderly patients (cases 1–3), and only one case was an adolescent
male [5].
We herein report these 4 HSTCL cases of Japanese patients.2. Case presentation
The clinical and laboratory features of these 4 cases are sum-
marized in Table 1 (cases 1–4). None of the patients had previous
illness that was related to immunodeﬁciency, immunosuppression or
an abnormal immunological status. All of the patients had B symp-
toms, hepatosplenomegaly and cytopenias at diagnosis, resulting in a
high or high-intermediate International Prognostic Index (IPI).
Case 1 was a 74-year-old female. A liver biopsy demonstrated the
inﬁltration of small to medium-sized lymphoma cells in the sinu-
soids and portal area, and these cells were CD3(þ), CD4(), CD5
(), CD8(), CD56(þ), TIA-1(þ), granzyme B() and Epstein–Barr
virus-encoded RNA (EBER) in situ hybridization() (Fig. 1). The
patient had a CR by treatment with 6 cycles of CHOP, and has re-
mained alive for more than 12 months after achieving a CR.
Case 2 was a 64-year-old male. A liver biopsy demonstrated the
inﬁltration of small to medium-sized lymphoma cells in the sinusoidsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of the 4 cases of HSTCL.
Case no. Age (y)/Sex Country Immuno-deﬁciency Clinical stage (cs) B symptoms Hepato-megaly Spleno-megaly IPI
1 74/F Japan  ⅣB þ þ þ High
2 64/M Japan  ⅣB þ þ þ High
3 59/M Japan  ⅣB þ þ þ High
4 23/M Japan  ⅣB þ þ þ High-int
Peripheral blood Histological detec-
tion of tumor cells
WBC
(109/L)
Hgb
(g/dL)
Platelet
(109/L)
Elevated LD
(U/L)
anti-
HTLV1
5.9 7.2 109 449  Liver, BM
1.8 12.2 54 390  Liver, BM
0.3 5.2 25 577  BM
7.1 9.1 95 522  BM
Immunohistochemical staining of tumor cells Outcome/follow-up (months)
CD2 CD3 CD4 CD5 CD7 CD8 CD56 TIA-1 Granzyme B EBER TCR
þ þ   þ  þ þ   γδ Alive/12M
þ þ   þ þ þ þ þ  γδ Dead/37M
NS þ   NS  NS NS NS  NS Dead/11M
þ þ   þ   þ   γδ Dead/19M
PS, performance status; IPI, International Prognostic Index; WBC, leukocyte count; Hgb, hemoglobin level; LD, lactate dehydrogenase level; BM, bone marrow; EBER, EB
virus-encoded small RNAs; TCR, T-cell receptor; PSL, Prednisolone; NS, not speciﬁed
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(þ), CD56(þ), TIA-1(þ), granzyme B(þ) and EBER(). He was
treated with 6 cycles of THP-COP (pirarubicin, cyclophosphamide,
vincristine and prednisolone) to achieve a PR for 10 months. Combi-
nation chemotherapy with 2 cycles of CHASE (cyclophosphamide,
cytarabine, etoposide and dexamethasone) was administered after the
disease progression, however, the tumor cells inﬁltrated the central
nervous system. He ultimately died 37 months after the diagnosis.
Case 3 was a 59-year-old male. A bone marrow clot demon-
strated hypercellular bone marrow with medium- to large-sized
lymphoma cells that were CD3(þ), CD4(), CD5(), CD8() and
EBER(). He was initially treated with 2 cycles of CHOP followed
by 2 cycles of ESHAP (etoposide, methylprednisolone andFig. 1. Histologic appearance of the liver in Case 1. (A) Lymphoma cells inﬁltrated the
munohistochemical analysis showed that the malignant cells were positive for CD3 andcytarabine), resulting in a PR. An autologous stem cell transplan-
tation preceded by a preparative regimen MCEC (ranimustine,
carboplatin, etoposide and cytarabine) provided a CR. He relapsed
3 months post-transplant and died 11 months after the diagnosis.
Case 4 was a 23-year-old male. A bone marrow biopsy de-
monstrated hypercellular bone marrow with medium- to large-
sized lymphoma cells that were CD3(þ), CD4(), CD5(), CD8
(), CD56(), TIA-1(þ), granzyme B() and EBER(), as pre-
viously reported [5]. He was treated with 1 cycle of CHOP followed
by 3 cycles of IVAC (ifosfamide, etoposide and cytarabine), re-
sulting in a PR. Allogeneic bone marrow transplantation from an
unrelated donor preceded by a preparative regimen composed of
etoposide, cyclophosphamide and total body irradiation providedsinusoids of the liver (hematoxylin and eosin stain, 200 ). (B), (C), (D) An im-
TIA-1, and negative for CD5.
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after the diagnosis.3. Discussion
HSTCL predominantly occurs in young men, with a median age
of 34 years. There have been few reports showing its frequency
separated by age, but only 4 out of 90 cases (4.4%) undergoing
stem cell transplantation have been reported as patients over 60
years of age [1]. In addition, HSTCL is believed to be related to
immunodeﬁciency. In our institution, 3 out of the 4 HSTCL cases
developed HSTCL after middle age, including an aged case at 74
years of age. All of these 4 cases had no previous illness. However,
other disease phenotypes and their inferior prognoses were si-
milar to the typical HSTCL cases.
Six HSTCL over 65 years of age have been reported in detail to
date. The clinical and histopathological characteristics of the pa-
tients are summarized in Table 2 (cases 5–10) [6–10]. These
characteristics, as well as our aged cases (Case 1) (Table 1), were
also compatible with the typical HSTCL cases. Notably, three of
these 7 aged HSTCL cases including our Case 1 were from Japan.
A possible mechanism of the initiation of HSTCL is a prolonged
immunosuppressive status which generates the expansion of γδ
T-cells recognizing multiple pathogens through excessive anti-
genic stimulation. Our cases did not have any previous illness re-
lated to immunosuppression, recurrent infectious episodes or la-
boratory evidence of HTLV-1 infection which has the potential ofTable 2
Summary of aged HSTCL cases in the literature.
Case no. Age (y)/Sex Country Immuno-
deﬁciency
5 71/M Japan PSL for BOOP
6 67/M Japan 
7 80/F U.S 
8 69/M U.S 
9 65/M U.S 
10 65/M U.S 
Summary (N¼6) Range: 65–80 /M 5; F 1 U.S: 4 Japan: 2 1/6
Peripheral blood
WBC (109/L)/Leukocytopenia Hgb (g/dL)/Anemia Platelet (109/L)/Thrombocytop
3.4 10.8 71
4.9 NS 85
3.7 14.1 55
12.2 NS þ
NS NS NS
NS þ þ
1/4 2/3 5/5
Immunohistochemical staining of tumor cells O
CD2 CD3 CD4 CD5 CD7 CD8 CD56 TIA-1 Granzyme B EBER TCR
NS þ   NS   þ þ þ γδ D
þ þ   þ þ  þ þ þ γδ A
NS þ  NS NS þ  þ þ  αβ D
þ þ   þ  þ þ   αβ D
þ þ   þ þ þ NS NS  γδ A
þ þ   þ þ  þ NS  γδ A
4/4 6/6 0/6 0/5 4/4 4/6 2/6 5/5 3/4 2/6 γδ 4; αβ 2 A
PS, performance status; IPI, International Prognostic Index; WBC, leukocyte count; Hgb
virus-encoded small RNAs; TCR, T-cell receptor; PSL, Prednisolone; BOOP, bronchiolitis
In WBC counts, Hgb levels and platelet levels, available data are listed. In cases lacking
topenia, anemia and thrombocytopenia include a WBC less than 4.0109/L, Hgb level lcausing immunosuppression as well as a T-cell malignancy. The
cause of their immunocompromised status was therefore un-
known; an age-related decline in the immune function might be
responsible for the lymphomagenesis of HSTCL in these cases. In
addition, both of the two previous aged Japanese cases (cases
5 and 6) were positive for EBER (Table 2). In Eastern Asia, EBV
infection and reactivation are thought to contribute to the tu-
morigenesis of T-cell or natural killer (NK)-cell posttransplant
lymphoproliferative disorder (T-PTLD) and non-hepatosplenic/
non-cutaneous γδ peripheral T-cell lymphomas [7]. Although
EBER was undetectable in our cases, there might be a potential
contribution of EBV infection and reactivation to the development
of HSTCL in aged patients as well as other lymphoid malignancies
[6,7].
Regarding therapy management, the cases in this study were
treated with CHOP (cyclophosphamide, doxorubicin, vincristine
and prednisolone) or CHOP-like regimens as ﬁrst-line therapy. The
5-year overall survival (OS) rate has been reported to be 7% [3].
Cases 2–4 in fact had faint responses, and these cases were not
rescued by subsequent salvage therapies, autologous HSCT (auto-
HSCT) and allogeneic HSCT (allo-HSCT). The survival beneﬁt of
HSTCL cases using allo-HSCT has been reported in a limited
number of cases [11]; Considerable issues in allo-HSCT include the
treatment-related mortality [12]. However, the evaluable sample
size in the study was too small to estimate the risk of cytotoxic
effects, GVHD and relapse after allo-HSCT. Therefore, large-scale
studies are required to determine the indication for and appro-
priate strategy of allo-HSCT to improve the treatment outcome ofClinical stage
(CS)
B symptoms Hepato-
megaly
Spleno-
megaly
IPI
ⅣB þ þ þ High
ⅣB þ þ þ High
ⅣB þ þ þ High
ⅣB þ  þ High
Ⅳ NS þ þ ≧High-int
ⅣB þ þ þ High
CS IV 6/6 5/5 5/6 6/6 High 5/≧High-
int 1
Histological detection of tumor cells
enia Elevated LD (U/L) anti-HTLV1
1622 NS Liver, BM
2240  Liver
NS NS NT
NS NS NT
NS NS BM
NS NS BM
2/2 0/1 BM 3; Liver 2
utcome/follow-up (months) References
ead/3 days [6]
live/1M [7]
ead/4 days [8]
ead/18M [8]
live/3M [9]
live/NS [10]
live 3 (NS-3M); Dead 3 (3 days-18M)
, hemoglobin level; LD, lactate dehydrogenase level; BM, bone marrow; EBER, EB
obliterans organizing pneumonia; NS, not speciﬁed
detailed data, þ or  is shown. In the summary column at the bottom, leukocy-
ess than 12.0 g/dL and platelet less than 100109/L, respectively.
H. Kawai et al. / Leukemia Research Reports 5 (2016) 3–66HSTCL. Interestingly, Case 1, an exclusive female patient, achieved
a CR that was maintained after 6 cycles of CHOP. This result was
compatible with a previous retrospective analysis of 15 patients
that showed that the overall survival (OS) was signiﬁcantly pro-
longed in females than in males [13].
In conclusion, HSTCL occurred not only in young adulthood, but
also in the middle-aged to elderly population. Further analyses
with a greater accumulation of HSTCL cases are required to elu-
cidate the potential differences. Substantial experience of treat-
ment for elderly HSTCL patients and the development of new
treatment modalities with lower adverse events are necessary to
improve the prognosis of HSTCL.Author contributions
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